Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics

Aquestive Therapeutics, Inc. (AQST): $2.57

0.06 (-2.28%)

POWR Rating

Component Grades








AQST Price/Volume Stats

Current price $2.57 52-week high $2.95
Prev. close $2.63 52-week low $0.72
Day low $2.57 Volume 4,593,900
Day high $2.77 Avg. volume 905,278
50-day MA $2.39 Dividend yield N/A
200-day MA $1.96 Market Cap 171.59M

AQST Stock Price Chart Interactive Chart >


  • Growth is the dimension where AQST ranks best; there it ranks ahead of 98.06% of US stocks.
  • The strongest trend for AQST is in Growth, which has been heading up over the past 26 weeks.
  • AQST's current lowest rank is in the Momentum metric (where it is better than 6.62% of US stocks).

AQST Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AQST is -0.47 -- better than just 6.31% of US stocks.
  • AQST's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 6.65% of US stocks.
  • Over the past twelve months, AQST has reported earnings growth of -89.3%, putting it ahead of merely 14.97% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to AQUESTIVE THERAPEUTICS INC, a group of peers worth examining would be NTGR, CTSO, DDD, QMCO, and AMST.
  • Visit AQST's SEC page to see the company's official filings. To visit the company's web site, go to

AQST Valuation Summary

  • In comparison to the median Healthcare stock, AQST's EV/EBIT ratio is 349.32% lower, now standing at -36.4.
  • AQST's price/earnings ratio has moved up 22.6 over the prior 66 months.

Below are key valuation metrics over time for AQST.

Stock Date P/S P/B P/E EV/EBIT
AQST 2023-12-29 2.8 -1.3 -11.1 -36.4
AQST 2023-12-28 2.8 -1.3 -11.0 -36.1
AQST 2023-12-27 2.8 -1.3 -11.1 -36.2
AQST 2023-12-26 2.8 -1.3 -11.0 -36.1
AQST 2023-12-22 2.8 -1.3 -11.0 -36.1
AQST 2023-12-21 2.6 -1.2 -10.5 -35.0

AQST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AQST has a Quality Grade of C, ranking ahead of 63.9% of graded US stocks.
  • AQST's asset turnover comes in at 0.73 -- ranking 38th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AQST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.730 0.693 -0.361
2021-06-30 0.692 0.690 -0.456
2021-03-31 0.808 0.750 -0.415
2020-12-31 0.760 0.717 -0.515
2020-09-30 0.858 0.692 -0.487
2020-06-30 0.929 0.686 -0.524

AQST Price Target

For more insight on analysts targets of AQST, see our AQST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.20 Average Broker Recommendation 1.4 (Strong Buy)

Aquestive Therapeutics, Inc. (AQST) Company Bio

Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.

AQST Latest News Stream

Event/Time News Detail
Loading, please wait...

AQST Latest Social Stream

Loading social stream, please wait...

View Full AQST Social Stream

Latest AQST News From Around the Web

Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 27, 2023

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Yahoo | December 26, 2023

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Yahoo | December 13, 2023

Best Momentum Stock to Buy for December 7th

AQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023.

Yahoo | December 7, 2023

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Yahoo | December 7, 2023

Read More 'AQST' Stories Here

AQST Price Returns

1-mo 7.53%
3-mo 20.66%
6-mo 55.76%
1-year 217.28%
3-year -43.89%
5-year -68.03%
YTD 27.23%
2023 123.92%
2022 -76.81%
2021 -27.29%
2020 -8.08%
2019 -7.62%

Continue Researching AQST

Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:

Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!